South Africa’s Biovac signs deal to produce oral cholera vaccine

accreditation
0:00
play article
Subscribers can listen to this article
A vial labelling machine at Biovac.
A vial labelling machine at Biovac.
Zakiyah Ebrahim


The Biovac Institute, a partly state-owned vaccine producer in South Africa, has secured a deal to make an oral cholera inoculation as recent global outbreaks of the diarrheal disease have raised demand for vaccines. 

The agreement with the International Vaccine Institute includes both licensing and technology transfer and is significant for Biovac because drug substance manufacturing capability will be built. 

Being able to produce the raw material needed to make vaccines is one of the last steps manufacturers on the continent are widely missing and will help scale up the local production of clinical trial products in Africa.

"The Covid-19 pandemic exposed Africa’s lack of local production capacity," Morena Makhoana, the chief executive officer of Biovac, said in a statement Wednesday.

"It became clear that increasing self-sufficiency is important if Africa is to have better control over its own public health and vaccine supply chains."Less than 1% of the world’s vaccines are made in Africa, even as infectious diseases are the leading cause of death on the continent, especially in children younger than five years old. Cholera is contracted by ingesting contaminated food or water and kills as many as 143 000 people globally each year, according to the World Health Organisation.

Climate change, armed conflict and displacements have added to the risk of cholera outbreaks including in Haiti, Pakistan, Nigeria and Malawi.Biovac has been ramping up its ability to make vaccines and in September produced its first batch of Covid-19 shots. This was part of an arrangement to fill and package as many as 100 million doses a year of Pfizerand BioNtech’s inoculation. 

The technology transfer process for the oral cholera vaccine will start in January, with the first clinical trial batches expected to be produced in 2024. The first phase of the project will be supported by R120 million from Wellcome and the Bill & Melinda Gates Foundation.

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For 14 free days, you can have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today. Thereafter you will be billed R75 per month. You can cancel anytime and if you cancel within 14 days you won't be billed. 
Subscribe to News24
Rand - Dollar
17.36
-1.1%
Rand - Pound
21.29
-1.3%
Rand - Euro
18.29
-0.9%
Rand - Aus dollar
11.81
-1.5%
Rand - Yen
0.13
-1.2%
Gold
1,797.73
+0.5%
Silver
23.50
+1.9%
Palladium
1,963.22
+1.7%
Platinum
1,030.76
+2.1%
Brent Crude
76.15
-1.3%
Top 40
68,351
+0.1%
All Share
74,548
+0.1%
Resource 10
73,315
-0.7%
Industrial 25
92,605
+1.0%
Financial 15
15,401
-0.9%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot
Editorial feedback and complaints

Contact the public editor with feedback for our journalists, complaints, queries or suggestions about articles on News24.

LEARN MORE
Government tenders

Find public sector tender opportunities in South Africa here.

Government tenders
This portal provides access to information on all tenders made by all public sector organisations in all spheres of government.
Browse tenders